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Objective: To assess safety, pharmacokinetic, and pharmacodynamic properties of recombinant human follicle-stimulat-
ing hormone (FSH; Org 32489, Organon International, Oss, the Netherlands) after a single intramuscular injection in the
buttock.
Design: In a prospective study, safety variables, serum FSH, luteinizing hormone, inhibin, estradiol (females only), and
testosterone (males only) were evaluated up to a maximum of 11 days after injection of 300 IU recombinant FSH.
Setting: Four specialist Reproductive Endocrinology and Infertility units.
Volunteers: Fifteen men and women exhibiting all pituitary gonadotropin deficiency.
Result(s): A single bolus of 300 IU recombinant FSH was well tolerated, and no drug-related adverse effects were
noted. Comparison of before and after treatment safety variables, including serum antirecombinant FSH antibodies,
showed no changes of clinical relevance. Analysis of serum FSH levels revealed comparable elimination half-lives of
44 6 14 (mean 6 SD) and 32 6 12 hours in women and men volunteers, respectively. In contrast, peak FSH
concentrations were significantly lower in women than in men volunteers (4.3 6 1.7 versus 7.4 6 2.8 IU/L), and the
time required to reach peak levels of FSH was significantly longer in women than in men (27 6 5 versus 14 6 8 hours).
The area under the serum level versus time curve tended to be smaller in women than in men volunteers (339 6 105
versus 452 6 183 IU/L 3 hours), but the difference did not reach statistical significance. Together these data suggest
that recombinant FSH is absorbed from its intramuscular depot to a lower rate and extent in women than in men. In
both sexes a relationship between serum FSH levels and body weight was apparent. During the experimental period,
other hormones remained low at baseline levels or were only slightly increased.
Conclusion(s): Our findings indicate that recombinant FSH is well tolerated and that it is absorbed from its intramuscular depot
to a higher rate and extent in men than in women. After intramuscular administration, its half-life is in good agreement with that
previously reported for natural FSH. (Fertil Sterilt 1993;59:108–14. ©1993 by American Society for Reproductive Medicine.)
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Human follicle-stimulating hormone (FSH)
is a gonadotropic hormone produced by the
anterior pituitary gland, whose primary func-
tion is regulation of follicular growth in fe-
males and of spermatogenesis in males. Hor-
monal response is accomplished via specific
membrane receptors on granulosa cells and
Sertoli cells, causing adenylate cyclase activa-
tion and thereby secretion and/or synthesis of
various factors essential for target cell differ-
entiation and gamete maturation (1, 2).
The FSH molecule has a dimeric structure
of which both subunits are glycoproteins in
nature. The 92-amino acid a-chain and the
111-amino acid b-chain have each two N-
linked oligosaccharide chains presented as
complex heterogeneous multiantennary
structures (3). The variable degree of glyco-
sylation, especially of sialylation, creates a
spectrum of FSH isoforms with differences
in charge, bioactivities, and elimination half-
lives (4, 5).
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The expression of human FSH in Chinese hamster ovary
cells transfected with both subunit genes (6, 7) resulted in
the synthesis of intact human FSH (recombinant FSH). The
polypeptide backbone of recombinant FSH is identical to
that of natural FSH, whereas recombinant and natural car-
bohydrate structures are closely related (8). The charge het-
erogeneity and bioactivity of recombinant FSH were con-
firmed by chromatofocusing, receptor displacement, and by
in vitro and in vivo animal studies (9–11). In comparison
with commercially available urinary gonadotropin prepara-
tions, highly pure (99.9%) recombinant FSH appeared to
lack intrinsic luteinizing hormone (LH) activity and to ex-
hibit a very high specific bioactivity (.10,000 IU/mg pro-
tein). These properties prompted the further development of
recombinant FSH by means of clinical studies examining its
pharmacokinetic and antigenic properties in humans. This
first human exposure study was performed in gonadotropin-
deficient male and female volunteers to assess the safety and
tolerance and the pharmacokinetic and pharmacodynamic
properties of recombinant FSH after a single intramuscular
injection.
MATERIALS AND METHODS
Subjects and Study Design
Fifteen gonadotropin-deficient, but otherwise healthy,
volunteers (8 women and 7 men) participated in this four-
center study. The study protocol was approved by the local
ethics review committees, and written informed consent was
obtained from all volunteers. Nine subjects had panhypopi-
tuitarism, either primary (n 5 3) or secondary (n 5 6), due
to surgical removal of a nonmalignant pituitary tumor. Five
volunteers suffered from congenital isolated gonadotropin
deficiency, and one volunteer was diagnosed as weight-loss–
related hypothalamic hypogonadism. Autoimmunity was ex-
cluded by antinuclear and specific antirecombinant FSH
antibody assays. Subjects receiving estrogen/androgen re-
placement refrained from this therapy, which started 1 week
(oral therapy) or 3 weeks (intramuscular substitution) before
injection up to 1 week after injection while appropriate
thyroid and glucocorticoid therapy was continued. With the
exception of one male volunteer, all subjects had a history of
proven normal gonadal function; seven out of eight women
had one or more deliveries, and one woman and six men
subjects responded well to previous hormonal therapy.
Subjects received a single intramuscular injection of 300
IU recombinant FSH (Org 32489, CP 90073; Organon In-
ternational, Oss, the Netherlands) in 2 mL solvent in the
upper quadrant of the buttock. Blood samples were taken just
before injection and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12,
16 (optional), 24, 48, 72, 96, 120 (optional), 168, 216 (op-
tional), and 264 hours (11 days) after injection. Blood sam-
ples were centrifuged, and serum was stored in 0.5-mL
serovials at 220°C until analysis. Serum was assayed for
immunoactive FSH, immunoactive and bioactive LH, testos-
terone (T), estradiol (E2), and inhibin.
Safety Parameters
Safety analysis included clinical observations, i.e., blood
pressure, heart rate, and body temperature, as well as labo-
ratory assessments like routine urinalysis (pH, protein, ace-
tone, glucose, hemoglobin), blood biochemistry (sodium,
potassium, chloride, bicarbonate, phosphorus, calcium, glu-
cose, urea, creatinin, uric acid, alkaline phosphatase, alanine
and aspartate aminotransferase, lactic dehydrogenase, biliru-
bin, protein, albumin), and hematology (hemoglobin, hemat-
ocrit, erythrocytes, differentiated leucocytes, thrombocytes).
Serum samples were analyzed for the presence of antire-
combinant FSH antibodies using a sensitive radioimmuno-
precipitation assay and 125I-recombinant FSH as a tracer.
When testing a mixture of two mouse monoclonal antibodies
(MCAs) raised against recombinant FSH and recognizing an
a- and b-specific epitopes, the sensitivity of the assay was
0.5 pmol/L and the intra-assay and interassay coefficients of
variation (CV) ranged from 4.3% to 9.6% and from 0.8% to
2.7%, respectively. The induction of antirecombinant FSH
antibodies after recombinant FSH treatment was judged by
comparing before and after treatment samples according to
criteria, allowing a probability of a false-positive result of
,0.1%. All serum samples were tested in duplicate, and the
MCA mixture was used as a positive control in all experi-
ments.
Hormone Assays
Immunoreactive FSH and LH was measured by an im-
munofluorometric assay using the time-resolved fluoroim-
munoassay technique and reagent kits 1244-017 for human
FSH and 1244-31 for human LH (Delfia, Pharmacia, Woer-
den, the Netherlands). These two-site assays use a b-directed
capturing MCA and an a-directed europium-labeled detec-
tion MCA. The assays were performed as described by the
manufacturer using the Delfia instrumentation system and
MultiCalc software (Pharmacia). Follicle-stimulating hor-
mone and LH immunoreactivity was expressed in terms of
the 2nd International Reference Preparation (IRP) of pitu-
itary FSH (code no. 78/549) and the 2nd International Stan-
dard for pituitary LH (code no. 80/552). The sensitivity of
immunofluorometric assay was 0.05 IU/L for both gonado-
tropins, and the intra-assay and interassay CV were below
4.8% and 4.3% for FSH and 4.7% and 7.5% for LH, respec-
tively. The cross-reactivity of the FSH kit with LH was
,0.08% and of the LH kit with FSH ,0.01%.
Serum bioactive LH was measured in an in vitro mouse
Leydig cell bioassay as described in detail previously (10).
The sensitivity of this assay for serum samples using 2nd
International Standard 80/552 as the standard was 2 IU/L.
Serum T and E2 were assessed by radioimmunoassay
(RIA) using a coat-a-count T RIA (reagent kit TKTT1 DPC,
detection limit 0.27 nmol/L; Diagnostic Products Corpora-
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tion, Los Angeles, CA) and a double antibody E2 RIA
(reagent kit KE2D1 DPC, detection limit 11.6 pmol/L; Di-
agnostic Products Corporation). The intra-assay and interas-
say CV were ,9% and 13% for the T assay and ,4% and
5% for the E2 assay, respectively.
Serum inhibin levels were measured by RIA using an
antiserum (no. 1989) raised against purified bovine 31-kd
inhibin (12). Purified bovine 31-kd inhibin iodinated by
the lactoperoxidase method was used as a tracer. The
standard was a pool of human follicular fluid (FF; 280
U/mL) that was calibrated against a rete testis standard
preparation of defined bioactivity. The immunoactivity of
1 mU FF was equipotent of 0.121 pg recombinant human
inhibin (Biotech Australia, specific in vitro bioactivity
51.060 U/mg protein using World Health Organization
[WHO] standard 86/690 as the standard). The recombi-
nant a-subunit of human inhibin exhibited complete
cross-reactivity in this assay system. The standard pool,
which was diluted in plasma from castrated subjects,
provided dose responses parallel to the plasma dilution
curves. The sensitivity of the assay was 28 U/L and the
intra-assay and interassay CV were ,10%.
Data Analysis
The peak recombinant FSH concentration (Cmax) and the
time of its occurrence (Tmax) were taken from measured
serum level data. The area under the serum level versus time
curve (AUC) after a single dose of 300 IU was determined
by means of the trapezoidal rule from zero time up to infinity
(AUC0-`) under subtraction of the baseline. The elimination
half-life (t1⁄2) was calculated after baseline correction on the
basis of increases of FSH concentrations measured between
72 and 264 hours after injection, using log-linear regression.
Data are presented as mean 6 SD unless stated otherwise.
Curvefit coefficients (r) represent Pearson correlation coef-
ficients. Comparison of age, height, weight, and body mass
index (BMI) between male and female volunteers was per-
formed by means of the Wilcoxon’s test. Gender differences
of bioequivalence were tested in a one-way analysis of
variance (ANOVA). Differences were considered to be sta-
tistically significant if P # 0.05.
RESULTS
Volunteers
The mean age, weight, height, BMI, and serum gonado-
tropin levels at screening are listed in Table 1. No significant
differences between male and female volunteers with respect
to age, height, or weight were found, whereas BMI values
were higher (P 5 0.04) for the female volunteers. During
screening, serum FSH levels ranged between 0.12 and 1.08
IU/L in males and between 0.11 and 1.63 IU/L in females.
Serum LH levels were either undetectable (,0.05 IU/L) or
very low, resulting in individual levels between ,0.05 and
0.40 IU/L in females and between ,0.05 and 1.13 IU/L in
males.
Safety and Tolerance
A single injection of 300 IU recombinant FSH was well
tolerated, and no drug-related adverse experiences were
noted. Neither pain nor skin redness was observed at the site
of drug injection. Comparison of before and after treatment
safety variables, i.e., blood pressure, heart rate, body tem-
perature, blood biochemistry, hematology, and urinalysis,
revealed no changes of clinical significance. When screening
volunteers for the possible induction of antirecombinant
FSH antibodies, no post-treatment increases in 125I-FSH
binding were observed.
Pharmacokinetic Analysis
Individual and mean delta increases of serum FSH after
intramuscular injection of 300 IU recombinant FSH in seven
male and eight female volunteers are shown in Figure 1. In
all subjects, serum FSH levels were raised at 30 minutes
after injection, and 13 out of 15 volunteers returned to
baseline values 264 hours after injection. Individual phar-
macokinetic parameters, AUC, Cmax, Tmax, and t1⁄2, are pre-
sented in Table 2. Within the group of male volunteers, one
statistical outlier was identified by means of the Dixon test.
This subject (M2), with an extremely low body weight (42
kg) and extremely high AUC value (876 IU/L 3 hours), was
not included in mean values and was excluded from further
statistical analysis. The mean t1⁄2 of recombinant FSH was
not significantly different between sexes (44 6 14 versus
32 6 12 hours). In contrast, Cmax values were significantly
T A B L E 1
Clinical characteristics of volunteers.*
Age Weight Height BMI FSH LH
y kg cm kg/m2 IU/L IU/L
Females (n 5 8) 36 6 3 67 6 13 162 6 12 26.1 6 4.3† 0.54 6 0.34 ,0.17
Males (n 5 7) 31 6 7 62 6 11 171 6 13 21.3 6 1.7 0.63 6 0.57 ,0.36
* Values are means 6 SD.
† Significantly higher in females than in males.
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(P 5 0.0072) lower in female than in male volunteers (4.3 6
1.7 versus 7.4 6 2.8 IU/L) and Tmax was also significantly
(P 5 0.0004) longer in females than in males (27 6 5 versus
14 6 8 hours). The mean AUC after administration of 300
IU recombinant FSH was 339 6 105 IU/L 3 hours in
females and 452 6 183 IU/L 3 hours in males and thus
tended to be lower in females, although the difference was
not statistically significant (P 5 0.058).
Relationship Between Body Weight and
Serum FSH Levels
Comparison of body weight and serum FSH levels re-
vealed a negative relationship in both men and women.
Although the number of subjects studied are limited, the data
suggest that there is a linear relationship between body
weight and Cmax values (males r 5 0.85; females r 5 0.83)
and between body weight and AUC values (males r 5 0.89;
females r 5 0.86). Scatter plots illustrating these associa-
tions are presented in Figure 2. The apparent linear relation-
ships between BMI and Cmax values (males r 5 0.48; fe-
males r 5 0.61) and between BMI and AUC values (males
r 5 0.51; females r 5 0.65) were less strong (data not
shown).
Other Hormones
Serum LH levels were assessed during screening (see
Table 1), just before injection, and at 1 and 3 days thereafter.
Mean immunoreactive before and after treatment LH levels
were below 0.4 IU/L for all subjects. Serum samples of five
female and five male volunteers were also tested in the in
vitro LH bioassay, but serum bioactive LH was below the
detection limit of the assay (,2 IU/L) in all cases.
In female volunteers, E2 was detectable (.9.9 pmol/L) in
only three women; 2 days after injection, two women
showed a slight increase in E2 (24 and 33 pmol/L, respec-
tively). Serum inhibin was either undetectable (,30 U/L) or
very low in female volunteers, whereas six out of seven
males had detectable levels of inhibin. In comparison with
baseline values, the mean inhibin of these six men was
doubled (238 6 91 versus 124 6 66 U/L) 3 days after
recombinant FSH injection. Serum T was either undetectable
(,0.27 nmol/L) in two men or low (,10 nmol/L) in others,
and no changes of any significance were noted (data not
shown).
DISCUSSION
For nearly 30 years, infertility treatment with gonado-
tropins has been based on the application of crude urinary
gonadotropin preparations, which have been proven safe and
effective. The future of gonadotropin therapy, however, is
likely to lie with highly pure recombinant human FSH prep-
arations, devoid of other gonadotropins or inactive contam-
inants. Furthermore, FSH production by means of recombi-
nant DNA technology is thought to guarantee an improved
batch to batch consistency.
T A B L E 2
Individual and mean pharmacokinetic parameters of
recombinant FSH after one single intramuscular injection in
the gluteal area in females (F) and males (M).
AUC Cmax Tmax t1⁄2
IU/L 3 hours IU/L/h h h
F1 506 6.9 36 43
F2 255 2.8 35 35
F3 244 2.4 24 69
F4 252 3.1 24 40
F5 287 3.4 24 63
F6 292 3.8 24 33
F7 454 6.1 24 37
F8 425 5.9 24 31
Mean 6 SD 399 6 105 4.3 6 1.7* 27 6 5† 44 6 14
M1 744 10.0 24 42
M2‡ 876 18.4 10 40
M3 367 8.1 9 34
M4 599 10.9 10 44
M5 355 4.4 9 38
M6 250 4.1 24 12
M7 393 6.9 10 25
Mean 6 SD 452 6 183 7.4 6 2.8 14 6 8 32 6 12
* Significantly lower in females than in males.
† Significantly longer in females than in males.
‡ Statistical outlier not included in mean values.
F I G U R E 1
Individual and mean delta increases of serum immunoreac-
tive FSH after intramuscular injection of 300 IU recombinant
FSH in seven men (A) and eight women (B) with hypogona-
dotropic hypogonadism.
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A general concern of recombinant glycoproteins is their
potential immunogenicity. Because the peptide backbone
structures of the natural and recombinant FSH were known
to be identical, this concern was limited to possible minor
differences in tertiary structure due to host cell processing.
This first clinical study with recombinant FSH was per-
formed in gonadotropin-deficient volunteers to minimize
possible hazards in case of an antirecombinant FSH immune
response and to prevent interference with endogenous gona-
dotropins. To date, many patients have been treated success-
fully with other recombinant glycoproteins, like erythropoi-
etin, without developing specific antibodies (13). In the
present study, no serum antirecombinant FSH antibodies
were detected, but further studies will be required to dem-
onstrate the safety of recombinant FSH during repeated
administrations and long-term infertility therapy.
After intramuscular injection, the release rate of gonado-
tropins may depend on the formulation, injection depth, site,
and volume (14). After intramuscular injection in the but-
tock, the absorption of immunoreactive recombinant FSH
was very slow and even significantly slower in women than
in men. Analysis of serum samples taken up to 72 hours after
injection revealed that immunoreactive FSH levels were in
good agreement with circulating bioactive FSH measured by
an in vitro granulosa cell bioassay (Huhtaniemi I, personal
communication).
Pharmacokinetic studies with urinary FSH and human
menopausal gonadotropin (hMG) preparations administered
via the intramuscular route have been limited but demon-
strated previously that serum FSH levels depend on both the
absorption and excretion rate of the drug. Diczfalusy and
Harlin (15) reported that t1⁄2 of hMG after intramuscular
administration (.40 hours) is about four times longer than
after intravenous injection. Daily injection of 150 or 225 IU
urinary FSH in three women with isolated gonadotropin
deficiency revealed a mean t1⁄2 of 36 6 16 hours, whereas t1⁄2
varied between 33 and 59 hours in normal men after single
intramuscular administration (16). The t1⁄2 of recombinant
FSH in the present study seems to be in good agreement with
those reported for urinary FSH/hMG, although this is the
first report on different release rates of FSH in men and
women. Pharmacokinetic parameters like Tmax and Cmax are
defined by the release of the drug from the intramuscular
depot and by its t1⁄2. However, the latter was not significantly
different between the sexes; seeming differences may be
attributed to the large intersubject variability. Sex differ-
ences in drug absorption and bioavailability after injection of
aqueous solutions in the gluteus maximus, rather than in the
vastus lateralus or deltoid, have been described previously
and are thought to be related to the gluteal fat thickness,
which is known to be greater in women than in men (14).
Consequently, women may receive part of the drug in their
subcutaneous adipose layer rather than intramuscular, lead-
ing to a less rapid absorption. Whether the latter also results
in a lower absolute bioavailability, as indicated by the rela-
tive small mean AUC of the female volunteers, remains to be
assessed.
Various studies support the hypothesis that body weight is
a major determining factor on the dose and length of gona-
dotropin stimulation for induction of ovulation and for in
vitro fertilization (17, 18). Follicle-stimulating hormone
doses to initiate ovarian response may vary largely between
individuals (19), and also thereafter major differences in
ovarian response require close treatment monitoring. The
present study revealed a strong negative correlation between
body weight and serum FSH levels after recombinant FSH
administration, thus suggesting that adjustment of doses of
FSH in relation to body weight could reduce ovarian re-
sponse variability.
In the current study, all volunteers, one man excepted,
had previous proof of normal gonadal function. In view of its
slow disappearance rate after intramuscular injection, a sin-
gle injection of recombinant FSH might have been sufficient
to induce temporarily gonadal response, influencing directly
or indirectly the synthesis of other hormonal factors. During
the experimental period, circulating immunoactive and bio-
active LH levels were extremely low or undetectable, as
previously reported for patients with hypogonadotropic hy-
pogonadism (20). Accordingly, serum T and E2 levels were
very low in male and female volunteers, respectively, and
only two out of eight women showed a very small E2 rise 2
F I G U R E 2
Correlation of Cmax (A) and AUC (B) with body weight in
seven men and eight women with hypogonadotropic hypog-
onadism.
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days after injection. Follicle-stimulating hormone-induced
E2 synthesis, however, is known to be impaired in hypogo-
nadotropic subjects (21–23), most likely because the minute
amounts of residual LH are too low to support E2 biosyn-
thesis adequately. Interestingly, six out of seven men volun-
teers showed slightly increased serum inhibin levels 3 days
after recombinant FSH injection. Using antiserum against
bovine 31-kd inhibin, comparable levels of inhibin in men
with hypogonadotropic hypogonadism were reported by oth-
ers (24). The fact that no inhibin increases were observed in
the female volunteers might be related to the relatively lower
availability of recombinant FSH in these subjects.
In conclusion, the data of this first human exposure study
with recombinant FSH (Org 32489, Organon International)
suggest that it is a safe drug with pharmacokinetic properties
comparable with those previously reported for natural FSH.
Further clinical data will be required to confirm the safety
and efficacy of recombinant FSH in infertile patients treated
for induction of ovulation or for induction of controlled
ovarian superovulation.
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